PHILADELPHIA and NEW YORK, Oct. 26, 2020 /PRNewswire/ --Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that BrainStorm has selected RR&D as its partner toexpedite site selection and design services for a state-of-the-art manufacturing facility for NurOwn (autologous MSC-NTF) in the U.S.
BrainStorm is investigating NurOwn as a potential treatment for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). BrainStorm's most advanced clinical program for NurOwn is in ALS, which is currently being evaluated in a pivotal Phase 3 clinical trial.
BrainStorm seeks to locate, design and construct a new commercial manufacturing facility in the U.S. to prepare for potential commercialization. RR&D, a three-firm services alliance consisting of EwingCole, Facility Logix and Biggins, Lacy, Shapiro & Company, will identify the location and develop the design of BrainStorm's new commercial manufacturing facility.
"We're thrilled to be working with BrainStorm on this project and to have the opportunity to deliver this critical work to our region," said EwingCole CEO, Jared Loos, PE, AIA. "We embrace the spirit of creating potentially life-changing technology and we will do everything we can to move the project forward in an efficient and yet responsible manner."
BrainStorm intends to use the facility primarily for cell therapy production. RR&D will provide custom, streamlined project management, site selection analysis and design/construction management services throughout the project's lifecycle.
Chaim Lebovits, Chief Executive Officer of BrainStorm Cell Therapeutics commented, "Our decision to partner with RR&D was driven by the strong capabilities of the individual partners and their holistic approach to planning, site selection and design services. The expansion of BrainStorm's manufacturing capabilities is a key part of our broader corporate strategy to prepare for potential regulatory approvals of NurOwn and becoming a commercial organization. This new partnership follows our recently announced agreement with Catalent Pharma Solutions to manufacture NurOwn at a scale large enough to meet potential commercial needs at the time of launch. The dedicated, state-of-the-art manufacturing facility developed by RR&D will provide us with important long-term autonomy and strategic flexibility, including the capacity to supply NurOwn for additional disease indications beyond ALS. Together these two partnerships will help ensure that BrainStorm has the manufacturing capacity to meet the needs of patients today and well into the future."
Site selection analyses will begin immediately with the goal of identifying locations that offer a cost-effective solution for BrainStorm's new manufacturing facility. At the same time, the design team will begin developing a conceptual design of the manufacturing facility, based upon input from BrainStorm's process, engineering, and scientific staff, by defining the main steps of the production process and Current Good Manufacturing Practices (cGMP) requirements. The approximately 50,000 square-foot building will contain manufacturing suites, complementary support and infrastructure, and the ability to expand the facility to 100,000 square feet to anticipate future programmatic needs.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(FDA) and theEuropean Medicines Agency(EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at sixU.S.sites supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a filing forU.S.FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently receivedU.S.FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) completed enrollment inAugust 2020. For more information, visit the company's website atwww.brainstorm-cell.com.
About Rapid Reshore & Development:
Rapid Reshore & Development is an alliance of expert firms providing confidence and support throughout the life sciences industry, representing an evolution from transaction-driven service models to a holistic focus on client needs, integrating an interdisciplinary team customized for a variety of individual projects. To optimize and strengthen confidence in decision-making and speed-to-market, Rapid Reshore & Development alliance was formed to deliver best-in-class professionals with deep experience in all aspects of life sciences' project planning, site selection, design and execution including financial, labor market, development incentives, real estate, design and engineering, and construction management.For additional information, visit: http://www.rapidreshore.com
Safe-Harbor Statement
Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
CONTACTS
Brainstorm:Investor Relations: Corey Davis, Ph.D. LifeSci Advisors, LLC Phone: +1 646-465-1138[emailprotected]
Media:Paul TyahlaSmithSolvePhone: + 1.973.713.3768[emailprotected]
Rapid Reshore & Development (RR&D):Media Contact:Zachary DeRitisCommunications Specialist215-409-4249[emailprotected]
SOURCE BrainStorm Cell Therapeutics Inc.; Rapid Reshore & Development (RR&D)
Go here to read the rest:
Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's US Manufacturing Facility...
- The Science Of Health: Are Spinal Cord Injuries Irreversible? Know Science Advances That Can Cure Them In The Future - ABP Live - October 16th, 2023
- Biden Weaponized Health Care on Abortion, Transgender, COVID-19 - Daily Signal - April 23rd, 2023
- Can This Company's Research Help Transform Regenerative Medicine As Its Lead Product Receives FDA IND Approval? - Marketscreener.com - November 17th, 2022
- BIOADAPTIVES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - November 17th, 2022
- With fewer inmates (and officers), Michigan closes another prison - Bridge Michigan - September 12th, 2022
- Testol 140 Review, Real Testol-140 Reviews Before and After Results - Dailyuw - September 12th, 2022
- Can California deliver on its zero-emission car goal? - Los Angeles Times - September 12th, 2022
- Researchers revive abandoned technique in effort to make artificial human eggs in a test tube - STAT - August 3rd, 2022
- 'Incredibly prejudicial': Why Sacramento courts have caged cells, and why that'll change - Walla Walla Union-Bulletin - August 3rd, 2022
- Ethical Issues in Stem Cell Research - PubMed Central (PMC) - December 22nd, 2021
- Dream Body Clinic Stem Cell Therapy Stem Cells HGH - December 22nd, 2021
- Stem cells | healthdirect - December 22nd, 2021
- Human Embryonic Stem Cells | The Embryo Project Encyclopedia - December 22nd, 2021
- Stem cells, through a religious lens Harvard Gazette - December 22nd, 2021
- Scientists identify 2nd HIV patient whose body rid itself of virus - National Herald - November 21st, 2021
- Need to streamline research on CRISPR gene-editing technology: Experts - Business Standard - November 21st, 2021
- Atrial Fibrillation Market Growth Driven by Technological Advancements in AFib Systems and Solutions and Rapidly Increasing Geriatric Population -... - November 21st, 2021
- Could Regenerative Biology Work in Humans? - Harvard Magazine - July 21st, 2021
- Alberta and NWT Bishops OK vaccination for COVID Grandin Media - Grandin Media - December 3rd, 2020
- The way prisoners flag guard abuse, inadequate health care and unsanitary conditions Is broken - injusticewatch.org - December 3rd, 2020
- From Roaches To Medical Emergencies, Illinois Inmates Say Theres Nobody That We Can Really Go To For Help - WBEZ - December 3rd, 2020
- Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS (ravulizumab) with Significantly Reduced Infusion... - November 20th, 2020
- California's Stem Cell Agency Will Get A Funding Boost From Prop 14. Here's A Look At Its History. - Capital Public Radio News - November 19th, 2020
- Stem Cell Banking Market is Projected to Reach $6,956 million by 2023 | Leading key players are Cord Blood Registry, ViaCord, Cryo-Cell, China Cord... - November 19th, 2020
- Locked up during the Waupun COVID surge - Wisconsin Examiner - November 19th, 2020
- Panelists debate the implications and ethics of stem cell research - Johns Hopkins News-Letter - November 2nd, 2020
- Is the Pro-Life Movement on a Collision Course with the Coronavirus? - The Dispatch - November 2nd, 2020
- Will Trevor Lawrence stay at Clemson to avoid the Jets? - Yahoo! Voices - November 2nd, 2020
- Spurs' Becky Hammon honored with impressive San Antonio mural - Yahoo! Voices - November 2nd, 2020
- Total Student Enrollment of China New Higher Education Group Achieves Strong Organic Growth to a New Record High -- Total Number of Enrolled Students... - November 2nd, 2020
- Elis announces the acquisition of 3 laundries in Brazil - Yahoo Finance UK - November 2nd, 2020
- Stem Cell Banking Market is forecast to reach $6,956 million by 2023 | ViaCord,Cryo-Cell, China Cord Blood Corporation, Cryo-Save - The Daily... - October 2nd, 2020
- Those linked to stem cell board received more than $2.1 billion - Capitol Weekly - September 16th, 2020
- Patenting Stem Cell Inventions in India- What to Expect? - Lexology - September 13th, 2020
- Global Stem Cell Banking Market Is Projected To Witness Vigorous Expansion By 2026 - Kewaskum Statesman News Journal - September 13th, 2020
- How Close Are We To Making Babies from Bone Marrow? - Discover Magazine - August 12th, 2020
- India could bleed itself dry amidst covid-19 crisis owing to blood shortage - ETHealthworld.com - July 12th, 2020
- Court rules controversial stem cell research is legal - July 10th, 2020
- Legal Issues in Stem Cell Therapy in the U.S. - Inventus Law - June 19th, 2020
- Restoring vision to the blind - Science Magazine - May 22nd, 2020
- Death of a Survivor - The New Republic - May 4th, 2020
- Could Cannabis Be an Effective Treatment for COVID-19? - Lab Manager Magazine - April 29th, 2020
- The Republicans who were once so pro-life they fought over one woman on life support now want to sacrifice grandma for the economy - The Independent - April 29th, 2020
- Russia's Humanitarian Law Obligations to Civilians in Occupied Ukrainian Territories in the Time of COVID-19 - Just Security - April 29th, 2020
- Merck Boosts Commercial Viral Vector and Gene Therapy Manufacturing Capacity - PR Newswire UK - April 22nd, 2020
- Insights Into the $8.8 Billion Cell Therapy Industry, 2020-2027 - Rising Adoption of Regenerative Medicine, Introduction of Novel Platforms &... - March 17th, 2020
- The tragic life of Meredith Vieira - Nicki Swift - March 17th, 2020
- The 411 on Stem Cells: What They Are and Why It's Important to Be Educated - Legal Examiner - February 20th, 2020
- The Challenge of Bioethics to Decision-Making in the UK - Westminster Abbey - February 20th, 2020
- Penn announces seven 2020 Thouron Award winners - Penn: Office of University Communications - February 20th, 2020
- BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week - GlobeNewswire - January 7th, 2020
- Drugs, Biologics, and Regenerative Medicine in 2019: A Successful Year Ends with Promise of a More Challenging 2020 - JD Supra - December 21st, 2019
- Edited Transcript of MRKR.OQ earnings conference call or presentation 12-Nov-19 10:00pm GMT - Yahoo Finance - November 29th, 2019
- BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update - GlobeNewswire - November 19th, 2019
- What to Know in Washington: Trump Ally in Impeachment Spotlight - Bloomberg Government - November 19th, 2019
- Do transhumanists need their own bill of rights? - Quartz - October 27th, 2019
- Does Stem Cell Therapy Work For Back Pain? - Regenexx - October 8th, 2019
- The Ethical, Social & Legal Issues of Cloning Animals ... - October 8th, 2019
- An Overview of Stem Cell Research | The Center for ... - October 5th, 2019
- Ethical Issues in Stem Cell Research | Endocrine Reviews ... - October 2nd, 2019
- Embryo - Wikipedia - October 2nd, 2019
- Legal Issues in Stem Cell Therapy in the U.S. - Royse Law Firm - September 14th, 2019
- Research With Stem Cells | American Medical Association - May 23rd, 2019
- Practical Problems with Embryonic Stem Cells - usccb.org - March 17th, 2019
- Stem Cells For Dummies: The Controvery, Pros and Cons ... - March 6th, 2019
- Human cloning - Wikipedia - February 18th, 2019
- stem cell | Definition, Types, Uses, Research, & Facts ... - December 12th, 2018
- Timeline of major events in stem cell research policy ... - August 25th, 2018
- stem-cells | ETHICAL, LEGAL, AND SOCIAL ISSUES - July 29th, 2018
- The Legal and Ethical Issues of Cloning That Make it ... - October 11th, 2017
- 5 Ethical and Legal Issues | Cord Blood: Establishing a ... - September 21st, 2017
- FDA Grants Orphan Drug Status to Cellect's ApoGraft for Acute GvHD and Chronic GvHD - PR Newswire (press release) - September 5th, 2017
- Of cell phones and swords things Amarilloans should know about new state laws - Amarillo.com - September 1st, 2017
- Cellect Shares Will Be Traded From Next Week Exclusively on NASDAQ - PR Newswire (press release) - September 1st, 2017
- ICMR to release stem cell research guidelines soon - BSI bureau (press release) - September 1st, 2017
- ICMR's stem cell research guidelines soon to be released - ETHealthworld.com - August 31st, 2017
- Should your medical data be off the record? - The Irish Times - Irish Times - August 25th, 2017
- Combatting the spread of anti-vaccination sentiment - OUPblog (blog) - August 25th, 2017
- Embryonic stem cell - Wikipedia - August 24th, 2017
- How processing health data has become increasingly problematic - Irish Times - August 24th, 2017